Abstract
Abstract: BACKGROUND: This study aims to evaluate the knowledge levels of chat generative pretrained transformer (ChatGPT), Bing, and Bard programs, which are three different artificial intelligence chatbots offered to the market free of charge by various manufacturers, regarding neuro-ophthalmological diseases, to examine their usability, and to investigate the existence of their superiority to each other. MATERIALS AND METHODS: Forty questions related to neuro-ophthalmological diseases were obtained from the study questions’ section of the American Academy and Ophthalmology 2022–2023 Basic and Clinical Science Course Neuro-ophthalmology Book. The questions were posed to the ChatGPT, Bing, and Bard artificial intelligence chatbots. The answers were evaluated as correct or incorrect. The statistical relationship between the correct and incorrect answer rates offered by the artificial intelligence programs was tested. RESULTS: The correct answer rates were given by the artificial intelligence programs to the questions asked: ChatGPT – 52.5%; Bing – 55%; and Bard – 65%. There was no statistically significant difference between the correct answer rates of the three artificial intelligence programs (P = 0.489, Pearson’s Chi-square test). CONCLUSION: Although information about neuro-ophthalmological diseases can be accessed quickly and accurately using up-to-date artificial intelligence programs, the answers given may not always be correct. Care should always be taken when evaluating the answers to the questions.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.